Best Organ Transplant in Indore

Organ transplantation replaces a failing organ with a functioning one from a living or deceased donor when medical management can no longer sustain life or an acceptable quality of life. For kidney failure, the indication is end-stage renal disease where dialysis is required or imminent. For liver failure, the indication is when the MELD score reflects a level of disease severity where transplantation improves survival over continued medical management.

CARE CHL Hospitals, Indore provides kidney transplantation with dedicated transplant ICUs, a multidisciplinary team covering all relevant specialities, rigorous pre-transplant evaluation, liver transplant consultation and follow-up, and lifelong immunosuppression management - within a single programme that does not require patients from Madhya Pradesh to travel to Mumbai or Delhi.

Kidney transplantation with the full pre-transplant evaluation, operative programme and post-transplant nephrology follow-up. Liver transplant consultation, pre-transplant assessment and post-transplant hepatology monitoring. Dedicated transplant ICU care and transplant coordinator support at every stage.

Yes. Live-related and cadaveric kidney transplants are performed at CARE CHL Hospitals, Indore. Donor evaluation, recipient workup, immunological crossmatch and post-transplant nephrology follow-up are all within the same programme. Pre-emptive transplantation before a patient reaches dialysis dependence is actively considered for eligible candidates with a suitable live donor.

Yes. Liver transplant candidacy assessment covering MELD score, hepatic imaging, cardiac fitness, psychological evaluation and eligibility review is available at CARE CHL Hospitals, Indore. The programme also covers management of decompensated cirrhosis while a patient awaits transplant, and post-transplant hepatology follow-up including immunosuppression, graft function monitoring and long-term complication surveillance.

Kidney transplantation is indicated for end-stage renal disease from diabetic nephropathy, hypertensive kidney disease, glomerulonephritis, polycystic kidney disease or other causes of irreversible renal failure. Liver transplantation is indicated for end-stage disease from alcohol-related cirrhosis, chronic hepatitis B or C, NASH cirrhosis, autoimmune hepatitis, Wilson’s disease, biliary conditions and hepatocellular carcinoma within Milan criteria.

Eligibility is established through formal multidisciplinary evaluation: organ failure severity, medical fitness for major surgery, absence of active malignancy and uncontrolled infection, no absolute contraindications, and psychological readiness with adequate social support. There is no fixed age threshold, though older candidates receive more thorough cardiovascular assessments. The transplant team gives patients and families an honest, individual assessment.

Tests include:

• Blood group and crossmatch
• HLA typing
• Full haematology and coagulation
• Liver and kidney function
• Viral serology (hepatitis B and C, HIV, CMV, EBV)
• ECG and echocardiogram
• CT abdomen for surgical anatomy
• Chest imaging
• Pulmonary function testing. 
• For live kidney donors, CT angiography maps the renal vasculature before operative planning.

A living donor gives a kidney or liver lobe electively - surgery is planned, timing is predictable and both operations proceed together. A deceased donor transplant uses an organ from a brain-dead individual whose family has consented; organ allocation goes through the state coordination network, timing cannot be predicted and the team must be ready to respond within hours. Both are performed at CARE CHL Hospitals, Indore.

Ask whether a formal multidisciplinary team reviews every candidate before listing; whether dedicated transplant ICUs are in place rather than shared general beds; whether the pre-transplant workup includes psychological and social assessment; whether post-transplant follow-up is structured and long-term; and whether dedicated coordinators are part of the programme. These are the features that separate a capable transplant programme from a general surgical service that occasionally performs transplants.

Yes Post-transplant patients with acute deterioration (fever, rising graft markers, abdominal pain or signs of rejection or infection) are assessed promptly with a transplant ICU available for intensive management. For cadaveric transplants, the team responds at any hour. Acutely unwell transplant recipients should call the transplant coordinator or go directly to the Emergency Department.

Advanced technologies are:

• Laparoscopic platforms for live donor nephrectomy
• Intraoperative ultrasound and ICG fluorescence imaging for hepatic and biliary assessment during liver transplantation
• Cell salvage for blood conservation
• Continuous haemodynamic monitoring in the transplant ICU
• Molecular crossmatch with solid-phase HLA antibody assays for immunological risk stratification.

Yes HPB surgeons, hepatologists, nephrologists, transplant anaesthetists, critical care intensivists, transplant coordinators, clinical psychologists and social workers ae all part of the transplant programme at CARE CHL Hospitals, Indore. Every transplant decision is a collective one.

Follow-up is most intensive in the first three months, with weekly then fortnightly review of drug levels, graft function and clinical status. Review intervals extend as the graft stabilises, with annual structured review continuing indefinitely. Immunosuppression is adjusted throughout. Post-transplant care at CARE CHL Hospitals, Indore is a long-term commitment, not a short course that ends at discharge.

Most recipients see a substantial improvement in quality of life compared with end-stage organ failure or dialysis. Returning to work, normal activity and social engagement within months of a successful transplant is realistic for the majority. The ongoing requirements like lifelong immunosuppression, regular monitoring and vigilance for rejection or infection are real but manageable, and most recipients consider them a worthwhile trade-off for a functioning graft.

Lifelong immunosuppression is non-negotiable after transplant. The standard regimen combines a calcineurin inhibitor, an antiproliferative agent and low-dose corticosteroids, adjusted over time. Prophylactic antimicrobials are given early post-transplant. Stopping immunosuppression without medical direction risks rejection, even in patients who feel completely well.

After a transplant you should:

• Take immunosuppression exactly as prescribed and never adjust doses independently. 
• Report fever, graft tenderness or any change in urine output or liver function immediately. 
• Avoid live vaccines under immunosuppression. 
• Use sun protection consistently given the elevated skin cancer risk. 
• Attend every scheduled monitoring appointment.

CARE CHL Hospitals, Indore provides kidney transplantation, liver transplant consultation, dedicated transplant ICUs, multidisciplinary team assessment and coordinator support.

Yes patients assessed for transplantation elsewhere who want an independent review of their candidacy, operative plan or post-transplant management can seek a second opinion at CARE CHL Hospitals, Indore. Existing imaging, biochemistry, histopathology and evaluation records are assessed and a clear independent view is provided. 

Transplant coordinators at CARE CHL Hospitals, Indore are involved from the first consultation. They explain the evaluation process, coordinate pre-transplant investigations and MDT appointments, manage the administrative and legal requirements of transplantation, handle the rapid response when a cadaveric organ is allocated and remain the primary point of contact through the post-transplant period. For many families, the coordinator is the person they speak to most.

The primary benefit is survival and quality of life as transplantation significantly extends life expectancy over continued organ failure or dialysis, and most recipients report substantially better daily function. Operative risks include bleeding, biliary or urological complications and vascular thrombosis. Post-operative risks include rejection, opportunistic infection, drug toxicity, post-transplant diabetes and elevated malignancy risk from immunosuppression. Every candidate's risk-benefit balance is assessed individually.

Kidney transplant recipients typically spend three to five days in the transplant ICU and are discharged around one to two weeks post-operatively and full return to normal activity takes two to four months. Liver transplant recipients spend five to ten days in the ICU and are discharged around two to three weeks post-operatively; return to normal activity takes three to six months. The first three months after either transplant carry the highest risk for rejection and infection and require intensive outpatient monitoring.

Yes. Nutritional counselling covering protein intake, post-transplant diabetes management, metabolic complication monitoring and food safety precautions under immunosuppression is part of the post-transplant programme at CARE CHL Hospitals, Indore. Physical activity progression and return to function are guided by the clinical team, with physiotherapy input where recovery requires it.

Appointments with the transplant team can be made by calling CARE CHL Hospitals, Indore directly, through the online booking platform or by attending the outpatient department. The transplant coordinator team can advise on what to bring to the initial evaluation. For post-transplant patients with acute deterioration, attend the Emergency Department directly or call the transplant coordinator immediately.

CARE CHL Hospitals, Indore manages the complete transplant pathway within a single programme ranging from initial candidacy evaluation and multidisciplinary assessment through pre-transplant workup, surgery, transplant ICU care, structured long-term follow-up and nutritional rehabilitation making it a comprehensive transplant destination for patients across Madhya Pradesh.